NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

Insight Molecular Diagnostics Inc. (IMDX) Stock Analysis

Insight Molecular Diagnostics Inc. (IMDX) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

IMDX

$4.13

+$0.01 (+0.24%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IMDX with… →

IMDX Key Statistics

As of Sep 4, 2026
Trading
Open
$4.10
Previous Close
$4.12
Day's Range
3.99–4.18
52-Week Range
2.40–8.51
Volume
183.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.80
Valuation
Market Cap
$135.15M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
80.93
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.52
Financials (FY)
Revenue (FY)
$4.06M+115.58%
Net Income (FY)
−$50.22M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
32.72M
1-Year Return
+67.21%
Dividend and dates
Earnings Date
November 9, 2026
Avg Volume
212.75K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IMDX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−44.93%
2025+215.13%
2024−4.80%
2023−61.06%
2022−85.21%
2021−9.21%
2020+6.22%
2019+63.04%
2018−70.32%
2017−34.04%
2016 (partial year)+71.53%

As of September 4, 2026.

IMDX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$4.06M−$50.22M−1238.5%
2024$1.88M−$60.66M−3225.0%
2023$1.50M−$27.78M−1848.4%
2022$958.00K−$72.90M−7609.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.06M$2.30M−$30.58M−$50.22M−1238.5%
2024$1.88M$740.00K−$23.25M−$60.66M−3225.0%
2023$1.50M$413.00K−$22.42M−$27.78M−1848.4%
2022$958.00K−$18.00K−$28.85M−$72.90M−7609.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IMDX Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricIMDXDiagnostics & Research medianvs median
P/S ratio80.934.9916.2x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Insight Molecular Diagnostics Inc. (IMDX) is capitalised at $135.15M on the latest close. The company sits in the Healthcare sector, in the Diagnostics & Research industry. The company reports 55 employees.

Over the past 52 weeks the price has ranged from $2.40 to $8.51. IMDX last closed at $4.13 on September 4, 2026. That is +$0.01 (+0.24%) against the previous close. The latest close sits 71.87% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $4.06M. Against the prior fiscal year total of $1.88M, that is a change of +115.58%. The same year closed with a net loss of $50.22M. Profit margin runs at 0%. Trailing earnings per share are −1.52.

Across the 4 fiscal years on file, revenue moves from $958.00K in 2022 to $4.06M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 80.93. On price-to-sales that is 16.2 times the Diagnostics & Research median of 4.99. 49 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.8. Annualized volatility over the trailing 10 years is 118.43%. The trailing one-year price return is +67.21%. Measured over 10 years, that is −24.67% a year compounded.

Growth & Income

The record shows no dividend for IMDX.

Across the complete calendar years on file, 2025 returned +215.13% and 2022 returned −85.21%. Of the 9 complete calendar years on file, 3 finished higher. 2026 is still running; the price is −44.93% year to date.

Peer Comparison

Insight Molecular Diagnostics Inc. (IMDX) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Insight Molecular Diagnostics Inc. IMDX $135.15M —
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. Insight Molecular Diagnostics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.

Visit website →